Home › NCT05927428

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

An Open-Label, Multi-Center, Phase 2 Dose Ranging Study of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Be at least 18 years of age;
* Provide written informed consent;
* Patients with NK Stage 2 (PED) or Stage 3 (corneal ulcer);

Exclusion Criteria:

* Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation not related to NK;
* Anticipated need to use therapeutic contact lenses or contact lens wear for refractive correction during the 28-days Treatment Period in the eye(s) with NK;
* Be a woman of childbearing potential who is not using an acceptable means of birth control;

About the study

The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.

What is being tested

• BRM424 Ophthalmic Solution - Dose1 (drug)
• BRM424 Ophthalmic Solution - Dose2 (drug)

Sponsor: BRIM Biotechnology Inc. · Participants: 12 · Started: Jul 31, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT05927428

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.